• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Barbara Weber, M.D., Elected to ITM Supervisory Board

    4/9/25 5:00:00 AM ET
    $BNTX
    $GSK
    $NVS
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTX alert in real time by email

    Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep expertise as it advances its lead Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and continues advancing its radiopharmaceutical pipeline and medical radioisotope manufacturing business. 



    "Dr. Weber's impressive track record in building transformative oncology biotech companies speaks volumes for her business acumen and her dedication to improving the lives of people living with cancer. Her profound industry and scientific knowledge, including her demonstrated ability to bring novel compounds through the clinic to FDA approval, will be an invaluable asset to ITM," said Udo J. Vetter, Chairman of the Supervisory Board of ITM. "The expansion of our Supervisory Board and its insights ensures that ITM is optimally positioned to continue accelerating the growth of its radiopharmaceutical pipeline and medical radioisotope business."

    Dr. Weber is a physician-scientist with a distinguished clinical and academic career and extensive leadership expertise in global pharmaceutical development. As the President, Chief Executive Officer and Founder of Tango Therapeutics, she led the company's transition to being publicly listed and the development of its precision oncology product candidates based on the genetic principle of synthetic lethality. As a Venture Partner at Third Rock Ventures, she led teams in creating new oncology drug discovery companies, including Tango Therapeutics, Neon Therapeutics (acquired by BioNTech (Nasdaq: BNTX)) and Relay Therapeutics (NASDAQ:RLAY).

    "As a physician and business executive devoted to fighting cancer, I recognize the significant potential of targeted radiopharmaceutical therapy to improve the precision oncology treatment paradigm and outcomes for patients. I look forward to working with ITM's Supervisory Board and Leadership Team as the company plans an NDA submission for ITM-11 and expands its pipeline with various promising alpha- and beta-emitting radioisotopes coupled with novel targeting agents," said Dr. Weber.

    Prior to her tenure at Third Rock Ventures, Dr. Weber was Senior Vice President, Oncology Translational Medicine at Novartis and Vice President, Oncology Discovery and Translational Medicine at GlaxoSmithKline, where she was instrumental in leading clinical studies and obtaining FDA approvals for numerous drugs including Zykadia®, Kisqali®, Vijoice® and Promacta®. Dr. Weber received her Doctor of Medicine from the University of Washington and has been affiliated with the University of Pennsylvania, Yale University and the Dana-Farber Cancer Institute. She is a member of the Board of Directors at Tango Therapeutics, Revolution Medicines Inc. (NASDAQ:RVMD), Parabilis Medicines and Sesame Therapeutics.

    About ITM Isotope Technologies Munich SE

    ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

    ITM Contact

    Corporate Communications

    Kathleen Noonan/Julia Westermeir

    Phone: +49 89 329 8986 1500

    Email: [email protected]

    Investor Relations

    Ben Orzelek

    Phone: +49 89 329 8986 1009

    Email: [email protected]

    Attachments

    • 20250409_Barbara Weber, M.D., Elected to ITM Supervisory Board
    • Barbara Weber, M.D., Elected to ITM Supervisory Board


    Primary Logo

    Get the next $BNTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $GSK
    $NVS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    9/12/2025$72.00Strong Buy
    Raymond James
    Novartis AG
    $NVS
    9/12/2025$118.00Neutral → Sell
    Goldman
    Revolution Medicines Inc.
    $RVMD
    9/5/2025$99.00Buy
    Truist
    Relay Therapeutics Inc.
    $RLAY
    9/4/2025$15.00Buy
    Guggenheim
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    8/19/2025$75.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    8/15/2025$67.00Overweight
    Wells Fargo
    Novartis AG
    $NVS
    8/8/2025$123.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BNTX
    $GSK
    $NVS
    $RLAY
    SEC Filings

    View All

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    10/2/25 6:51:18 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    10/1/25 10:10:01 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    10/1/25 9:05:32 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

    4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 7:41:18 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Third Rock Ventures Iv, L.P. sold $4,008,500 worth of shares (500,000 units at $8.02) (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    9/29/25 4:15:05 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Cislini Jeff sold $79,624 worth of shares (1,799 units at $44.26), decreasing direct ownership by 3% to 50,425 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    9/26/25 4:13:13 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Wei Lin sold $98,982 worth of shares (2,160 units at $45.82), decreasing direct ownership by 2% to 88,339 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    9/18/25 4:39:39 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BNTX
    $GSK
    $NVS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

    New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track remains the only publicly accessible source for month-by-month immunization trends across a variety of adult vaccines, enabling analyses that could uncover possible drivers Vaccine Track can help public health organizations and providers identify gaps and better target their efforts GSK plc (LSE/NYSE:GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends acros

    10/1/25 10:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Multiple Myeloma Research Foundation Unites Patients and Advocates to Hike New Hampshire's White Mountains to Accelerate a Cure for Multiple Myeloma

    NORWALK, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation® (MMRF®) today announced that a team of hikers, including multiple myeloma patients and advocates, will take on the rugged trails of New Hampshire's White Mountains as part of the Moving Mountains for Multiple Myeloma® (MM4MM) program. Sponsored by GSK plc (LSE/NYSE:GSK), the trek aims to raise awareness of multiple myeloma and generate critical funds to accelerate a cure for multiple myeloma. The hike will take place October 5 – 9, 2025. "Now in its ninth year, MM4MM has made tremendous progress and united hundreds of patients, caregivers, and supporters to raise funds that go directly to advancing

    10/1/25 7:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

    Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring11.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolioEAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as a

    9/30/25 5:23:00 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Revolution Medicines with a new price target

    Raymond James resumed coverage of Revolution Medicines with a rating of Strong Buy and set a new price target of $72.00

    9/12/25 7:52:44 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novartis AG downgraded by Goldman with a new price target

    Goldman downgraded Novartis AG from Neutral to Sell and set a new price target of $118.00

    9/12/25 7:50:34 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Revolution Medicines with a new price target

    Truist initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $99.00

    9/5/25 8:01:04 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

    Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicte

    8/6/25 4:02:29 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

    Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb ("BMS") to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic transaction to acquire CureVac N.V. ("CureVac") to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidatesPresented multiple clinical update

    8/4/25 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the l

    7/30/25 4:05:25 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

    Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

    5/9/25 9:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $GSK
    $NVS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    11/14/24 1:22:38 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care